Corrigendum to "Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years" [Vaccine 40 (2022) 4190-4198]
Vaccine. 2024 Oct 3;42(23):126023.
doi: 10.1016/j.vaccine.2024.05.071.
Epub 2024 Jun 18.